109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
儿童血液系统恶性肿瘤患者血流感染的风险因素及临床管理策略
Authors Zhang Y, Sun L, Li X, Zhang R, Liu J, Li J
Received 21 May 2025
Accepted for publication 27 September 2025
Published 13 October 2025 Volume 2025:18 Pages 3303—3310
DOI https://doi.org/10.2147/RMHP.S535221
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Gulsum Kaya
Yaping Zhang,1,* Lijun Sun,2 Xiujuan Li,2 Rui Zhang,2 Jiaying Liu,2 Jiao Li2,*
1Department of Blood Transfusion, The Second Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China; 2Clinical Laboratory, Hebei Key Laboratory of Laboratory Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jiao Li, Clinical Laboratory, Hebei Key Laboratory of Laboratory Medicine, The second Hospital of Hebei Medical University, No. 215 Heping West Road, Shijiazhuang, Hebei, 050000, People’s Republic of China, Tel +86-0311-15832180219, Email 28400310@hebmu.edu.cn
Purpose: Chemotherapy remains the primary treatment for haematological malignancies (HMs). While recent therapeutic advances have improved patient survival, treatment-induced immunosuppression and prolonged neutropenia significantly elevate the risks of bloodstream infection (BSI), contributing to higher mortality. This study identifies risk factors for BSI in pediatric HM patients, aiming to establish evidence-based protocols for infection prevention and risk stratification, thereby informing targeted healthcare policies to reduce complications and improve treatment outcomes.
Patients and Methods: We retrospectively analyzed 682 pediatric HM patients presenting with fever at our institution, including 98 BSI-confirmed cases.Results were statistically compared across multiple aspects.
Results: Pediatric HM patients with bloodstream infection showed significantly higher AML prevalence (47.96% vs 33.22%, P = 0.005) and Gram-negative bacteria predominance (66.33%), notably Escherichia coli (E. coli) (27.55%). Stenotrophomonas maltophilia infection rates were significantly higher in lymphoma patients than in other hematological malignancies (P < 0.05). Multivariable analysis identified four modifiable risk factors: peak body temperature (OR = 5.468, 95% CI 3.407– 8.775, P < 0.001), duration of neutropenia (OR = 1.181, 95% CI 1.120– 1.245, P < 0.001), febrile neutropenia (OR = 8.193, 95% CI 3.574– 18.780, P < 0.001), and invasive procedures (OR = 4.265, 95% CI 1.920– 9.474, P < 0.001).
Conclusion: To reduce BSI complications in pediatric HM patients, we recommend implementing risk-stratified temperature protocols and strict neutropenia control (≤ 7 days), emphasizing rigorous clinical criteria for invasive procedures (PICC). These findings provide an evidence base for healthcare policies aimed at reducing infection-related mortality through optimized treatment protocols and enhanced clinical care standards.
Keywords: haematological malignancies, bloodstream infection, duration of neutropenia, invasive procedures, febrile neutropenia
1Department of Blood Transfusion, The Second Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China; 2Clinical Laboratory, Hebei Key Laboratory of Laboratory Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jiao Li, Clinical Laboratory, Hebei Key Laboratory of Laboratory Medicine, The second Hospital of Hebei Medical University, No. 215 Heping West Road, Shijiazhuang, Hebei, 050000, People’s Republic of China, Tel +86-0311-15832180219, Email 28400310@hebmu.edu.cn
Purpose: Chemotherapy remains the primary treatment for haematological malignancies (HMs). While recent therapeutic advances have improved patient survival, treatment-induced immunosuppression and prolonged neutropenia significantly elevate the risks of bloodstream infection (BSI), contributing to higher mortality. This study identifies risk factors for BSI in pediatric HM patients, aiming to establish evidence-based protocols for infection prevention and risk stratification, thereby informing targeted healthcare policies to reduce complications and improve treatment outcomes.
Patients and Methods: We retrospectively analyzed 682 pediatric HM patients presenting with fever at our institution, including 98 BSI-confirmed cases.Results were statistically compared across multiple aspects.
Results: Pediatric HM patients with bloodstream infection showed significantly higher AML prevalence (47.96% vs 33.22%, P = 0.005) and Gram-negative bacteria predominance (66.33%), notably Escherichia coli (E. coli) (27.55%). Stenotrophomonas maltophilia infection rates were significantly higher in lymphoma patients than in other hematological malignancies (P < 0.05). Multivariable analysis identified four modifiable risk factors: peak body temperature (OR = 5.468, 95% CI 3.407– 8.775, P < 0.001), duration of neutropenia (OR = 1.181, 95% CI 1.120– 1.245, P < 0.001), febrile neutropenia (OR = 8.193, 95% CI 3.574– 18.780, P < 0.001), and invasive procedures (OR = 4.265, 95% CI 1.920– 9.474, P < 0.001).
Conclusion: To reduce BSI complications in pediatric HM patients, we recommend implementing risk-stratified temperature protocols and strict neutropenia control (≤ 7 days), emphasizing rigorous clinical criteria for invasive procedures (PICC). These findings provide an evidence base for healthcare policies aimed at reducing infection-related mortality through optimized treatment protocols and enhanced clinical care standards.
Keywords: haematological malignancies, bloodstream infection, duration of neutropenia, invasive procedures, febrile neutropenia